Most potential drug candidates (90%) fail within the clinical trials, mainly because of lack of efficacy.
What if the pharmaceutical industry uses predictive human in vitro models in early drug discovery ?
Ask for a high quality version of this poster :
View and download on Slideshare (low quality) https://fr.slideshare.net/hcspharma/a-groundbreaking-3d-cell-culture-technology-for-hcs-biomimesys-hydroscaffold
Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.
This week we will present at the thematic school “From 3D culture to the organoid: multidisciplinary research” organised by the Institute of Biological Sciences of CNRS (France) in Strasbourg. Study director Méryl Roudaut will talk Read more…
It is our pleasure to announce that the article of our PhD Student Véronique De Conto has been published in Toxicology in vitro journal. This work comes from a collaboration between HCS Pharma and Inserm Read more…
2 Comments
SLAS Washington 2019: the evidence of 3D culture for drug discovery! | HCS Pharma · February 14, 2019 at 1:57 pm
[…] BIOMIMESYS® technology in a talk during the tutorial organized by Molecular Devices (see our poster here – if you want the presentation, please contact […]
Feedback from TERMIS congress in Nantes! by HCS Pharma | HCS Pharma · September 16, 2019 at 5:33 pm
[…] research. There we presented 3 posters – that you can find on our website! – about BIOMIMESYS® product range, about iPSC-derived hepatocytes in BIOMIMESYS® Liver, and about BIOMIMESYS® for organ-on-chip […]